Vedolizumab: a novel medical intervention in the treatment of primary sclerosing cholangitis

BMJ Case Rep. 2017 May 13:2017:bcr2017220351. doi: 10.1136/bcr-2017-220351.

Authors

Donevan Westerveld¹, Joseph Grajo², Lars Beattie³, Sarah Glover⁴

Affiliations

¹ Department of Internal Medicine, University of Florida, Gainesville, Florida, USA.
² Department of Radiology, University of Florida College of Medicine, Gainesville, Florida, USA.
³ Department of Emergency Medicine, University of Florida College of Medicine, Gainesville, Florida, USA.
⁴ Department of Gastroenterology, University of Florida College of Medicine, Gainesville, Florida, USA.

No abstract available

Keywords: Biliary intervention; Gastrointestinal system; Inflammatory bowel disease; Liver disease.

Publication types

Case Reports

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / therapeutic use*
Bile Ducts, Intrahepatic / diagnostic imaging
Bile Ducts, Intrahepatic / pathology
Cholangiopancreatography, Magnetic Resonance
Cholangitis, Sclerosing / complications
Cholangitis, Sclerosing / diagnostic imaging*
Cholangitis, Sclerosing / drug therapy*
Colitis, Ulcerative / complications
Colitis, Ulcerative / drug therapy
Constriction, Pathologic / diagnostic imaging
Constriction, Pathologic / etiology
Gastrointestinal Agents / therapeutic use*
Humans
Male
Middle Aged

Substances

Antibodies, Monoclonal, Humanized
Gastrointestinal Agents
vedolizumab